In vivo activity of ursolic and oleanolic acids during the acute phase of Trypanosoma cruzi infection

Experimental Parasitology

Volumn 134, Issue 4, 2013, Pages 455-459

  Da Silva Ferreira, Daniele ^a   Esperandim, Viviane Rodrigues ^a   Toldo, Miriam Paula Alonso ^b   Kuehn, Christian Collins ^b   Do Prado Júnior, José Clóvis ^b   Cunha, Wilson Roberto ^a   Silva, Márcio Luís Andrade e ^a   Albuquerque, Sérgio de ^b  

^a UNIVERSIDADE DE FRANCA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Interleukin; Oleanolic acid; Trypanosoma cruzi; Ursolic acid

Indexed keywords

BENZNIDAZOLE; GAMMA INTERFERON; INTERLEUKIN 10; LAFEPE; OLEANOLIC ACID; UNCLASSIFIED DRUG; URSOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IN VIVO STUDY; INFECTION CONTROL; INTESTINE ABSORPTION; MALE; MOUSE; NONHUMAN; PARASITEMIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TRYPANOSOMA CRUZI;

INTERLEUKIN; OLEANOLIC ACID; TRYPANOSOMA CRUZI; URSOLIC ACID;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFECTIVE AGENTS; CHAGAS DISEASE; DISEASE MODELS, ANIMAL; INFUSIONS, PARENTERAL; INTERFERON-GAMMA; INTERLEUKIN-10; MALE; MELASTOMATACEAE; MICE; MICE, INBRED BALB C; NITROIMIDAZOLES; OLEANOLIC ACID; PARASITEMIA; RANDOM ALLOCATION; TRITERPENES; TRYPANOCIDAL AGENTS;

MUS; TRYPANOSOMA CRUZI;

EID: 84878903539     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2013.04.005     Document Type: Article

References (37)

1. Ahmad S.F., Khan B., Bani S., Suri K.A., Satti A.K., Qazi G.N. Amelioration of adjuvant-induced arthritis by ursolic acid through altered Th1/Th2 cytokine production. Pharmacol. Res. 2006, 53:233-240.
2. Brener Z. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev. Inst. Med. Trop. Sao Paulo 1962, 4:389-396.
3. Cançado J.R. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev. Inst. Med. Trop. Sao Paulo 2002, 44:29-37.
4. Cardillo F., Voltarelli J.C., Reed S.G., Silva J.S. Regulation of Trypanosoma cruzi infection in mice by gamma inteferon and interleukin 10: role of NK cells. Infect. Immun. 1996, 64:128-134.
5. Coura J.R., Dias J.C. Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Mem. Inst. Oswaldo Cruz 2009, 104:31-40.
6. Cunha W.R., Crevelin E.J., Arantes G.M., Crotti A.E., Silva M.L.A., Furtado N.A., Ferreira D.S. A study of trypanocidal activity of triterpene acids isolated from Miconia species. Phytother. Res. 2006, 20:474-478.
7. Cunha W.R., Martins C., Da Silva Ferreira D., Crotti A.E., Lopes N.P., Albuquerque S. In vitro trypanocidal activity of triterpenes from Miconia species. Planta Med. 2003, 69:470-472.
8. Cunha L.C.S., Silva M.L.A., Furtado N.A.J.C., Vinhólis A.H.C., Martins C.H.G., Da Silva Filho A.A., Cunha W.R. Antibacterial activity of triterpene acids and semi-synthetic derivatives against oral pathogens. Z. Naturforsch. 2007, 62:668-672.
9. Croft S.L., Barrett M.P., Urbina J.A. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol. 2005, 21:508-512.
10. Da Silva Filho A.A., Resende D.O., Fukui M.J., Santos F.F., Pauletti P.M., Cunha W.R., Gregório L.E., Bastos J.K., Nanayakkara N.P.D. In vitro antileishmanial, antiplasmodial and cytotoxic activities of phenolics and triterpenoids from Baccharis dracunculifolia D. C. (Asteraceae). Fitoterapia 2009, 80:478-482.
11. Dias J.C.P. Elimination of Chagas disease transmission: perspectives. Mem. Inst. Oswaldo Cruz 2009, 104:41-45.
12. Ferreira D.S., Esperandim V.R., Toldo M.P.A., Saraiva J., Cunha W.R., Albuquerque S. Trypanocidal activity and acute toxicity assessment of triterpene acids. Parasitol. Res. 2010, 106:985-989.
13. Garcia S., Ramos C.O., Senra J.F.V., Vilas-Boas F., Rodrigues M.M., Carvalho A.C.C., Santos R.R., Soares M.B.P. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrob. Agents Chemother. 2005, 49:1521-1528.
14. Golden J.M., Tarleton R.L. Trypanosoma cruzi: cytokine effects on macrophage trypanocidal activity. Exp. Parasitol. 1991, 72:391-402.
15. Ikeda Y., Murakami A., Ohigashi H. Ursolic acid: an anti- and pro-inflammatory triterpenoid. Mol. Nutr. Food Res. 2008, 52:26-42.
16. Izumi E., Ueda-Nakamura T., Dias Filho B.P., Veiga Júnior V.F., Nakamura C.V. Natural products and Chagas' disease: a review of plant compounds studied for activity against Trypanosoma cruzi. Nat. Prod. Rep. 2011, 23:809-823.
17. Jeong D.W., Kim Y.H., Kim H.H., Ji H.Y., Yoo S.D., Choi W.R., Lee S.M., Han C.K., Lee H.S. Dose-linear pharmacokinetics of oleanolic acid after intravenous and oral administration in rats. Biopharm. Drug Dispos. 2007, 28:51-57.
18. Lirussi D., Li J., Prieto J.M., Gennari M., Buschiazzo H., Rios J.L., Zaidenberg A. Inhibition of Trypanosoma cruzi by plant extracts used in Chinese medicine. Fitoterapia 2004, 75:718-723.
19. Liu J. Oleanoic acid and ursolic acid: research perspectives. J. Ethnopharmacol. 2005, 100:92-94.
20. Maya J.D., Cassels B.K., Iturriaga-Vásquez P., Ferreira J., Faúndez M., Galanti N., Ferreira A., Morello A. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2007, 146:601-620.
21. Martín R., Carvalho-Tavares J., Hernández M., Arnés M., Ruiz-Gutiérrez V., Nieto M.L. Beneficial actions of oleanolic acid in an experimental model of multiple sclerosis: a potential therapeutic role. Biochem. Pharmacol. 2010, 79:198-208.
22. Minoprio P., El-Cheikh M.C., Murphy E., Hontebeyrie-Joskowicz M., Coffman R., Coutinho A., O'Garra A. Xid-associated resistance to experimental Chagas' disease is IFN-γ dependent. J. Immunol. 1993, 151:4200-4208.
23. Moreno M., D'avila D., Silva M.N., Galvão L.M.C., Macedo A.M., Chiari E., Gontijo E.D., Zingales B. Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease. Mem. Inst. Oswaldo Cruz 2010, 105:918-924.
24. Munõz Fernández M.A., Fernández M.A., Fresno M. Synergism between tumor necrosis factor-alpha and interferon-g on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide dependent mechanism. Eur. J. Immunol. 1992, 22:301-307.
25. Nataraju A., Saini D., Ramachandran S., Benshoff N., Liu W., Chapman W., Mohanakumar T. Oleanolic acid, a plant triterpenoid, significantly improves survival and function of islet allograft. Transplantation 2009, 88:987-994.
26. Reed S.G., Brownell C.E., Russo D.M., Silva J.S., Grabstein K.H., Morissey P.J. IL-10 mediates susceptibility to Trypanosoma cruzi infection. J. Immunol. 1994, 153:3135-3149.
27. Resende F.A., Barcala C.A.M.A., Faria M.C.S., Kato F.H., Cunha W.R., Tavares D.C. Antimutagenicity of ursolic acid and oleanolic acid against doxorubicin-induced clastogenesis in Balb/c mice. Life Sci. 2006, 79:1268-1273.
28. Rodriques Coura J., De Castro S.L. A critical review on Chagas' disease chemotherapy. Mem. Inst. Oswaldo Cruz 2002, 97:3-24.
29. Samudio M., Montenegro-James S., Cabral M., Martinez J., Rojas de Arias A., James M.A. Cytokine responses in Trypanosoma cruzi infected children in Paraguay. Am. J. Trop. Med. Hyg. 1998, 58:119-121.
30. Saúde-Guimarães D.A., Faria A.R. Substâncias da natureza com atividade anti-Trypanosoma cruzi. Rev. Bras. Farmacog. 2007, 17:455-465.
31. Silva J.S., Morriessey P.J., Grabstein K.H., Mohler K.M., Andreson D., Reed S.G. Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J. Exp. Med. 1992, 175:169-174.
32. Silva J.S., Vespa G.N.R., Cardoso M.A.G., Aliberti J.C.S., Cunha F.Q. Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect. Immun. 1995, 63:4862-4867.
33. Somova L.O., Nadar A., Rammanan P., Shode F.O. Cardiovascular, antihyperlipidemic and antioxidant effects of oleanolic and ursolic acids in experimental hypertension. Phytomedicine 2003, 10:115-121.
34. Song M., Hang T.J., Wang Y., Jiang L., Wu X.L., Zhang Z., Shen J., Zhang Y. Determination of oleanolic acid in human plasma and study of its pharmacokinetics in chinese healthy male volunteers by HPLC tandem mass spectromerty. J. Pharm. Biomed. Anal. 2006, 40:190-196.
35. Urbina J.A., Docampo R. Specific chemotherapy of Chagas' diasease: controversies and advances. Trends Parasitol. 2003, 19:495-501.
36. Vasconcelos M.A.L., Royo V.A., Ferreira D.S., Crotti A.E.M., Silva M.A.L., Carvalho J.C.T., Bastos J.K., Cunha W.R. In vivo analgesic and anti-Inflammatory activities of ursolic acid and oleanoic acid from Miconia albicans (Melastomataceae). Z. Naturforsch. 2006, 61:477-482.
37. WHO - World Health Organization, 2007. WHO's Certified (database on the Internet). Control of Chagas disease (cited 2011 Mar 16). Available from: http://whqlibdoc.who.int/trs/WHO_TRS_905.pdf.